Browse > Article
http://dx.doi.org/10.4014/jmb.1311.11052

Anticancer Effects of the Hsp90 Inhibitor 17-Demethoxy-Reblastatin in Human Breast Cancer MDA-MB-231 Cells  

Zhao, Qing (Faculty of Pharmacy, Bengbu Medical College)
Wu, Cheng-Zhu (Faculty of Pharmacy, Bengbu Medical College)
Lee, Jae Kyoung (Chemical Biology Research Center, KRIBB)
Zhao, Su-Rong (Faculty of Pharmacy, Bengbu Medical College)
Li, Hong-Mei (Faculty of Pharmacy, Bengbu Medical College)
Huo, Qiang (Faculty of Pharmacy, Bengbu Medical College)
Ma, Tao (Faculty of Pharmacy, Bengbu Medical College)
Zhang, Jin (Faculty of Pharmacy, Bengbu Medical College)
Hong, Young-Soo (Chemical Biology Research Center, KRIBB)
Liu, Hao (Faculty of Pharmacy, Bengbu Medical College)
Publication Information
Journal of Microbiology and Biotechnology / v.24, no.7, 2014 , pp. 914-920 More about this Journal
Abstract
Triple-negative breast cancer (TNBC) possesses a higher rate of distant recurrence and a poorer prognosis than other breast cancer subtypes. Interestingly, most of the heat shock protein 90 (Hsp90) client proteins are oncoproteins, and some are closely related to unfavorable factors of TNBC patients. 17-Demethoxy-reblastatin (17-DR), a novel non-benzoquinone-type geldanamycin analog, exhibited potent Hsp90 ATPase inhibition activity. In this study, the anticancer effects of 17-DR on TNBC MDA-MB-231 cells were investigated. These results showed that 17-DR inhibited cell proliferation, induced apoptosis, and suppressed cell invasion and migration in the MDA-MB-231 cells. Down-regulation of the key Hsp90-dependent tumor-driving molecules, such as RIP1 and MMP-9, by 17-DR may be related to these effects. Taken together, our results suggest that 17-DR has potential as a therapeutic agent for the treatment of TNBC.
Keywords
Hsp90; 17-demethoxy-reblastatin; anticancer effect; TNBC;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Hong YS, Lee D, Kim W, Jeong JK, Kim CG, Sohng JK, et al. 2004. Inactivation of the carbamoyltransferase gene refines post-polyketide synthase modification steps in the biosynthesis of the antitumor agent geldanamycin. J. Am. Chem. Soc. 126: 11142-11143.   DOI   ScienceOn
2 Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 69: 5898-5903.
3 Kim MS, Kwak HJ, Lee JW, Kim HJ, Park MJ, Park JB, et al. 2008. 17-Allylamino-17-demethoxygeldanamycin down-regulates hyaluronic acid-induced glioma invasion by blocking matrix metalloproteinase-9 secretion. Mol. Cancer Res. 6: 1657-1665.   DOI   ScienceOn
4 Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63.   DOI   ScienceOn
5 Kim W, Lee D, Hong SS, Na Z, Shin JC, Roh SH, et al. 2009. Rational biosynthetic engineering for optimization of geldanamycin analogues. Chembiochem. 10: 1243-1251.   DOI   ScienceOn
6 Kim W, Lee JS, Lee D, Cai XF, Shin JC, Lee K, et al. 2007. Mutasynthesis of geldanamycin by the disruption of a gene producing starter unit: generation of structural diversity at the benzoquinone ring. Chembiochem. 8: 1491-1494.   DOI   ScienceOn
7 Messaoudi S, Peyrat JF, Brion JD, Alami M. 2011. Heat shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010. Expert Opin. Ther. Pat. 21: 1501-1542.   DOI   ScienceOn
8 Mosser DD, Morimoto RI. 2004. Molecular chaperones and the stress of oncogenesis. Oncogene 23: 2907-2918.   DOI   ScienceOn
9 Sankhala KK, Mita MM, Mita AC, Takimoto CH. 2011. Heat shock proteins: a potential anticancer target. Curr. Drug Targets 12: 2001-2008.   DOI
10 Shin JC, Zhu N, Lee DH, Kim WC, Lee K, Shen YM, et al. 2008. Characterization of tailoring genes involved in the modification of geldanamycin polyketide in Streptomyces hygroscopicus JCM4427. J. Microbiol. Biotechnol. 18: 1101-1108.
11 Whitesell L, Lindquist SL. 2005. Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 5: 761-772.   DOI   ScienceOn
12 Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. 1994. Inhibition of heat shock protein 90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91: 8324-8328.   DOI   ScienceOn
13 Wu CZ, Jang JH, Ahn JS, Hong YS. 2012. New geldanamycin analogs from Streptomyces hygroscopicus. J. Microbiol. Biotechnol. 22: 1478-1481.   DOI   ScienceOn
14 Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, et al. 2008. Activation of fibronectin/PI3K/Akt leads to chemoresistance to docetaxel by regulating surviving protein expression in ovarian and breast cancer. Cancer Lett. 261: 108-119.   DOI   ScienceOn
15 Wu CZ, Jang JH, Woo M, Ahn JS, Kim SJ, Hong YS. 2012. Enzymatic glycosylation of nonbenzoquinone geldanamycin analogs via Bacillus UDP-glycosyltransferase. Appl. Environ. Microbiol. 78: 7680-7686.   DOI
16 Wrona IE, Gozman A, Taldone T, Chiosis G, Panek JS. 2010. Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90. J. Org. Chem. 75: 2820-2835.   DOI   ScienceOn
17 Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, et al. 2008. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer 122: 2050-2056.   DOI   ScienceOn
18 Zhang H, Burrows F. 2004. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 82: 488-499.
19 Zhao S, Ma W, Zhang M, Tang D, Shi Q, Xu S, et al. 2013. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med. Oncol. 30: 335.   DOI
20 Amend K, Hicks D, Ambrosone CB. 2006. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 66: 8327- 8330.   DOI   ScienceOn
21 Baichwal VR, Baeuerle PA. 1997. Activate NF-$\kappa{B}$ or die? Curr. Biol. 7: R94-R96.   DOI   ScienceOn
22 Bryan BB, Schnitt SJ, Collins LC. 2006. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod. Pathol. 19: 617-621.   DOI   ScienceOn
23 Groblewska M, Siewko M, Mroczko B, Szmitkowski M. 2012. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem. Cytobiol. 50: 12-19.   DOI
24 Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, et al. 2012. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 14: R62.   DOI   ScienceOn
25 Chiosis G, Vilenchik M, Kim J, Solit D. 2004. Hsp90: the vulnerable chaperone. Drug Discov. Today 9: 881-888.   DOI   ScienceOn
26 Da Silva VC, Ramos CH. 2012. The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics. J. Proteomics 75: 2790-2802.   DOI   ScienceOn
27 Han HZ. 2012. Research in progress of triple negative breast cancer molecular targeted therapy. Chinese Clin. Oncol. 17: 470-474.
28 Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, et al. 2008. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14: 7940-7946.   DOI   ScienceOn